OmniAb, Inc. (OABI)
(Delayed Data from NSDQ)
$4.08 USD
+0.01 (0.25%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $4.07 -0.01 (-0.25%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.08 USD
+0.01 (0.25%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $4.07 -0.01 (-0.25%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Zacks News
USANA Health Sciences (USNA) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
USANA Health (USNA) delivered earnings and revenue surprises of 24.64% and 2.03%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Plus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Plus (PSTV) delivered earnings and revenue surprises of 10.26% and 4.21%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -24.14% and 0.74%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
OmniAb, Inc. (OABI) Soars 10.5%: Is Further Upside Left in the Stock?
by Zacks Equity Research
OmniAb, Inc. (OABI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aclaris (ACRS) delivered earnings and revenue surprises of 18.92% and 344.14%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Ligand (LGND) Up 3% on Raised '23 View, Beats on Q1 Earnings
by Zacks Equity Research
Ligand Pharmaceuticals (LGND) announces better-than-expected results in first-quarter 2023. Management raises 2023 financial outlook.
Do Options Traders Know Something About OmniAb (OABI) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to OmniAb (OABI) stock based on the movements in the options market lately.
Ligand's (LGND) Q4 Sales & Earnings Top, View Raised, Stock Up
by Zacks Equity Research
Ligand Pharmaceuticals (LGND) announces better-than-expected results in fourth-quarter 2022. Stock is up in the after-market hours in response to the news. Management raises 2023 financial outlook.
Ligand (LGND) Beats on Q3 Earnings, Lags Sales, Ups '22 Outlook
by Zacks Equity Research
Ligand (LGND) reports mixed third-quarter 2022 numbers, beating sales estimates but missing out on earnings. Share price rises as management lifts financial guidance for the year.